# US 2026/0097125 A1 · Ultra-long-acting platform comprising fc-advanced fatty acid chain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097125 A1
- Document ID: US20260097125A1
- Status: Published application
- Kind: A1
- Application number: 19/113,341
- Filed: 2023-09-22
- Published: 2026-04-09
- Earliest claimed: 2022-09-26
- Assignees: Waterstone Pharmaceuticals(Wuhan) Co., Ltd.
- Applicants: Waterstone Pharmaceuticals (Wuhan) Co., Ltd.
- Inventors: Faming Zhang; Yimin Hu; Yuan Zhou; Yao Yu; Minglong Hu; Xiaolong Wang; Along Zhao; Ying Liang
- Web page: https://patentgrep.com/patent/US20260097125A1

## CPC

- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 38/26: Glucagons
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- C07K 14/605: Glucagons
- C07K 16/22: against growth factors {; against growth regulators}
- C07K 16/2818: {against CD28 or CD152}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to an ultra-long-acting platform for improving the half-life of an active molecule of a drug, which comprises immunoglobulin Fc and an advanced advanced fatty acid chain. The present invention also relates to preparation of the conjugate platform, a composition comprising the conjugate, and a treatment application thereof. The present invention specifically relates to a conjugated molecule having a structure of “active molecule-Fc-Cn”, wherein the active molecule is selected from any molecules beneficial to an organism, Fc is immunoglobulin IgG Fc, and Cn is a modified moiety comprising a C14-24 fatty acid chain. The present invention also relates to preparation of the conjugated molecule, a composition comprising the conjugate and a treatment application thereof.

## Claims

### Claim 1

A conjugated molecule having a structure of “active molecule-Fc-Cn”, wherein the active molecule is selected from any molecules beneficial to an organism, Fc is an immunoglobulin IgG Fc, and Cn is a modified moiety comprising a C14-24 fatty acid chain.

### Claim 2

A conjugated molecule having a structure of “antibody-Cn”, wherein Cn is a modified moiety comprising a C14-24 fatty acid chain.

### Claim 3

A conjugated molecule having a structure of “active molecule-fusion protein-Cn”, wherein the active molecule is selected from any molecules beneficial to an organism and Cn is a modified moiety comprising a C14-24 fatty acid chain.

### Claim 4 (depends on 1, 2, 3)

The conjugated molecule according to any of claims 1 to 3, wherein Cn has the structure of Formula (I):
wherein
Z has the following structure:
—Z1—Z2—Z3—Z4—,
wherein Z1 is a sulfur atom or a nitrogen atom or an oxygen atom in Fc,
Z2 is —C(═O)— or 5-10 membered heterocyclyl, preferably containing 1 or 2 heteroatoms selected from N, S, and O;
Z3 is selected from the group consisting of a bond, —C(═O)—, —C1-C10 alkylene-C(═O)—, —C3-C10 alkynylene-C(═O)—, —C3-C10 alkenylene-C(═O)—, —C1-C10 heteroalkylene-C(═O)—, —C3-C8 cycloalkylene-C(═O)—, —O—C1-C8 alkylene-C(═O)—, -arylidene-C(═O)—, —C1-C10 alkylene-arylidene-C(═O)—, -arylidene-C1-C10 alkylene-C(═O)—, —C1-C10 alkylene-C3-C8 cycloalkylene-C(═O)—, —C3-C8 cycloalkylene-C1-C10 alkylene-C(═O)—, —C3-C8 heterocyclylene-C(═O)—, —C1-C10 alkylene-C3-C8 heterocyclylene-C(═O)—, —C3-C8 heterocyclylene-C1-C10 alkylene-C(═O)—, wherein the alkylene, alkynylene, alkenylene, heteroalkylene, cycloalkylene, arylidene, and heterocyclylene are substituted optionally;
Z4 is a bond or a PEG unit represented by the following Formula,
wherein R1 is selected from the group consisting of C1-4 alkylene, —NH—, —NH—C1-4 alkylene-, —NH—C1-4 alkylene-heteroaryl-, wherein heteroaryl is 5-membered or 6-membered nitrogen-containing heteroaryl; R2 is —C(═O)—, —C1-4 alkylene, —C1-4 alkylene-C(═O)—, —C1-4 alkylene-NH—C(═O)—(CH2OCH2)p—C1-4 alkylene-, —C1-4 alkylene-C(═O)—NH—(CH2OCH2)p—C1-4 alkylene-, wherein m is an integer from 2 to 6, p is an integer from 1 to 3,
Y is
wherein Y is linked to Z4 via X, k is an integer from 10 to 30,
wherein R independently represents hydrogen, C1-6 alkyl, C1-6 aminoalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl.

### Claim 5 (depends on 1, 2, 3, 4)

The conjugated molecule according to any one of claims 1 to 4, wherein Z2 is maleimido group
wherein the wavy line on the left side indicates the position to which Z1 is linked; and the wavy line on the right side indicates the position to which Z3 is linked.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The conjugated molecule according to any one of claims 1 to 5, wherein Z3 is —C1-C10 alkylene-C(═O)—, wherein the alkylene is optionally substituted and wherein Z3 is linked to Z4 via —C—(═O)—.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The conjugated molecule according to any one of claims 1 to 6, wherein Z2 is a maleimido group and Z3 is —C1-6 alkylene-C(═O)—.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The conjugated molecule according to any one of claims 1 to 7, wherein Z4 is a bond and Z3 is directly linked to Y in Formula (I).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The conjugated molecule according to any of claims 1 to 8, wherein Z4 is a PEG unit represented by the following Formula:
wherein R1 is selected from the group consisting of —NH— and —NH—C1-4 alkylene-; R2 is —C1-4 alkylene or —C1-4 alkylene-NH—C(═O)—(CH2OCH2)p—C1-4 alkylene-, wherein m is an integer from 2 to 6 and p is an integer from 1 to 3.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The conjugated molecule according to any of claims 1 to 9, wherein Z4 is a unit comprising 2 to 6 PEGs.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The conjugated molecule according to any of claims 1 to 10, wherein Z4 is
wherein m=1-4, the asterisk on the left side indicates the position to which Z3 is linked; and the asterisk on the right side indicates the position to which Y is linked in Formula II.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The conjugated molecule according to any of claims 1 to 11, wherein Z in Formula (I) has the following structure:
wherein RE is hydrogen, C1-6 alkyl, C1-6 aminoalkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, wherein y=0-4, m=1-4, wherein the asterisk on the left side indicates the position to which Ab is linked and the asterisk on the right side indicates the position to which Y is linked.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The conjugated molecule according to any one of claims 1 to 12, wherein Y is linked to Z4 via X, and X is —NH—(C═O)— or —(C═O)—NH—.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The conjugated molecule according to any one of claims 1 to 13, wherein Cn comprises a C16 fatty acid chain, a Cis fatty acid chain, or a C20 fatty acid chain.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The conjugated molecule according to any of claims 1 to 14, wherein Cn comprises a C18 fatty acid chain and is conjugated to the sulfur atom of the free thiol group of Fc.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The conjugated molecule according to any of claims 1 to 15, wherein Cn is selected from

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The conjugated molecule according to any one of claims 1 to 16, wherein the Fc is IgG1 Fc or IgG4 Fc, preferably human IgG1 Fc or human IgG4 Fc.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The conjugated molecule according to any of claims 1 to 16, wherein the Fc-region further comprises an immunoglobulin IgG hinge region.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The conjugated molecule according to any of claims 1 to 17, wherein the Fc-region has a modification at an amino acid selected from positions 228, 233, 234, 235, 252, 254, 256, 297, 307, 308, 311, 380, 385, 386, 389, 428, 434, and 447 (according to EU numbering).

### Claim 20 (depends on 19)

The conjugated molecule according to claim 19, wherein the modification is to replace amino acids at positions 254, 308 and 434 with Thr, Pro and Ala, respectively (according to EU numbering).

### Claim 21 (depends on 20)

The conjugated molecule according to claim 20, wherein the modification is S228P, F234A and L235A, or S228P, F234A, L235A and 447 deletion (according to EU numbering).

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The conjugated molecule according to any one of claims 1 to 21, wherein the Fc-region comprises or consists of the sequence as set forth in SEQ ID NOs: 10, 15 or 16.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The conjugated molecule according to any one of claims 1 to 22, wherein the active molecule is an active peptidic molecule fused to the Fc-region either directly or via a peptide linker.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The conjugated molecule according to any one of claims 1 to 23, wherein the C-terminus of the active peptidic molecule is fused to the N-terminus of the Fc-region, or the N-terminus of the active peptidic molecule is fused to the C-terminus of the Fc-region.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The conjugated molecule according to any one of claims 1 to 24, wherein the active molecule is selected from an enzyme, an enzyme inhibitor, an antigen, an antibody or antibody fragment, a hormone, glucagon-like peptide-1 (GLP-1), glucagon, an interferon, a cytokine, a growth factor and/or a differentiation factor, a factor involved in cell motility or migration, a factor involved in bone formation/resorption, a chemokine, a plasma or interstitial adhesion molecule or extracellular matrix, a bactericidal or antifungal factor.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The conjugated molecule according to any one of claims 1 to 25, wherein the active molecule is selected from GLP-1, an antibody or an antigen-binding fragment thereof.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The conjugated molecule according to any one of claims 1 to 26, wherein the active molecule is selected from an anti-PD-1 antibody or an antigen-binding fragment thereof, an anti-VEGF antibody or an antigen-binding fragment thereof.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The conjugated molecule according to any one of claims 1 to 27, wherein the peptide linker comprises the amino acid sequence (G4S)n, wherein n is an integer equal to or greater than 1, preferably the peptide linker comprises (G4S)3, (G4S)4, (G4S)6, GS(G4S)4, DAAALEAAALDAAAREAAARDAAAL, NVDHLPSNTLVDLA, (G3S)2, (G4S)2, (G3S)3, (G4S)3, (G3S)4, (G4S)4, (G3S)5, (G4S)5, (G3S)6, (G4S)6, GGG, DGGGS, TGEKP, GGRR, EGKSSGSGSESKVD, KESGSVSSEQLAQFRSLD, GGRRGGGS, LRQRDGERP, LRQKDGGGSERP, and GSTSGSGK PGSGEGSTKG.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The conjugated molecule according to any one of claims 1 to 28, wherein the Fc comprises the sequence as set forth in SEQ ID NOs: 10, 15 or 16.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The conjugated molecule according to any one of claims 1 to 29, which is GLP-1-IgG4 Fc-TM1, GLP-1-IgG4 Fc-C18 tert-butanol ester, GLP-1-IgG4 Fc-C16-NHS, and GLP1-IgG4 Fc-C20-NHS.

### Claim 31 (depends on 30)

The conjugated molecule according to claim 30, wherein IgG4 Fc comprises the sequence as set forth in SEQ ID NO: 16.

### Claim 32 (depends on 30, 31)

The conjugated molecule according to claim 30 or 31, wherein the GLP-1-IgG4 Fc moiety in GLP-1-IgG4 Fc-TM1, GLP-1-IgG4 Fc-C18 tert-butanol ester, GLP-1-IgG4 Fc-C16-NHS, and GLP1-IgG4 Fc-C20-NHS conjugated molecule comprises the amino acid sequence as set forth in SEQ ID NO: 1.

### Claim 33 (depends on 27)

The conjugated molecule according to claim 27, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as set forth in SEQ ID NO: 9 and a light chain variable region as set forth in SEQ ID NO: 11.

### Claim 34 (depends on 33)

The conjugated molecule according to claim 33, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a heavy chain as set forth in SEQ ID NO: 8 and a light chain as set forth in SEQ ID NO: 12.

### Claim 35 (depends on 33, 34)

The conjugated molecule according to claim 33 or 34, wherein the Fc comprises the sequence as set forth in SEQ ID NO: 10.

### Claim 36 (depends on 35)

The conjugated molecule according to claim 35, which is a HX008-TM1 conjugated molecule, preferably a HX008-TM1-2 conjugated molecule or a HX008-TM1-3 conjugated molecule.

### Claim 37 (depends on 27)

The conjugated molecule according to claim 27, wherein the anti-VEGF antibody or antigen-binding fragment thereof comprises 3 heavy chain CDRs as set forth in SEQ ID NOs: 2, 3, and 4, and 3 light chain CDRs as set forth in SEQ ID NOs: 5, 6, and 7.

### Claim 38 (depends on 37)

The conjugated molecule according to claim 37, wherein the anti-VEGF antibody or antigen-binding fragment thereof comprises a heavy chain as set forth in SEQ ID NO: 13 and a light chain as set forth in SEQ ID NO: 14.

### Claim 39 (depends on 37, 38)

The conjugated molecule according to claim 37 or 38, wherein the Fc comprises the sequence as set forth in SEQ ID NO: 15.

### Claim 40 (depends on 37, 38, 39)

The conjugated molecule according to any one of claims 37 to 39, which is a HX006-TM1 conjugated molecule, a HX006-C18-tert-butanol ester conjugated molecule, a HX006-C16-NHS conjugated molecule, and a HX006-C20-NHS conjugated molecule.

### Claim 41

A method for the preparation of a conjugated molecule having a structure of “active molecule-Fc-Cn”, comprising
(a) linking an active molecule polypeptide to an immunoglobulin Fc-region to prepare an “active molecule-Fc” fusion; and
(b) subjecting the “active molecule-Fc” fusion and Cn containing a fatty acid chain to a conjugating reaction under the conditions that allow the conjugation of the Fc-region to Cn, resulting in an “active molecule-Fc-Cn” conjugated molecule.

### Claim 42

A method for the preparation of a conjugated molecule having a structure of “active molecule-Fc-Cn”, comprising the steps of
(a) linking the antibody Fab fragment to an immunoglobulin Fc-region to prepare a “Fab-Fc” fusion, and
(b) subjecting the “Fab-Fc” fusion to a conjugating reaction under the conditions that allow the conjugation of the Fc-region to Cn containing a fatty acid chain, resulting in a “Fab-Fc-Cn” conjugated molecule.

### Claim 43

A method for the preparation of a conjugated molecule having a structure of “active molecule-Fc-Cn” or having a structure of “antibody-Cn”, comprising the steps of subjecting a whole antibody to a conjugating reaction under the conditions that allow the conjugation of the Fc-region to Cn containing a fatty acid chain, resulting in an “active molecule-Fc-Cn” conjugated molecule.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

A pharmaceutical composition comprising the conjugated molecule of any one of claims 1 to 40.

### Claim 45 (depends on 41, 42, 43)

A method for effectively extending the serum half-life of an active molecule, comprising the step of constructing the active molecule as a conjugated molecule having a structure of “active molecule-Fc-Cn” or having a structure of “antibody-Cn” according to the method of any one of claims 41 to 43, thereby effectively increasing the serum half-life of the active molecule.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 44)

Use of the conjugated molecule of any one of claims 1 to 40 or the pharmaceutical composition of claim 44 in the manufacture of a medicament for the treatment of a human disease.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 44)

A method for the treatment of a human disease, comprising administering an effective amount of the conjugated molecule of any one of claims 1 to 40 or the pharmaceutical composition of claim 44 to a subject.
